Compare Neurocrine Biosciences Inc (NBIX) vs Banco Santander SA (SAN) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Neurocrine Biosciences Inc vs Banco Santander SA — how do they compare? Neurocrine Biosciences Inc trades at $155 (market cap $15.77B), while Banco Santander SA trades at $14.79 (market cap $218.36B). The key difference: Banco Santander SA is far larger — about 13.8× Neurocrine Biosciences Inc's market cap, and Banco Santander SA pays a 1.87% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | SAN | |
|---|---|---|
Market Cap | $15.77B | $218.36B |
Sector | Health | Financials |
52-Week High | $185.50 | $15.05 |
52-Week Low | $123.10 | $9.65 |
Enterprise Value | $15.78B | — |
Dividend Yield | — | 1.87% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Neurocrine Biosciences (NBIX) trades at $155.13, down 0.33% with a bearish technical signal. The company maintains strong fundamentals with 97.91% gross margins and 20.91% net income margin, supported by robust Ingrezza sales growth and Crenessity momentum. Recent news highlights institutional buying interest but also safety concerns around Vykat XR, contributing to recent price volatility.
NBIX presents a compelling growth story with strong profitability and analyst support (86% buy rating), though execution risks and drug safety issues warrant caution. The consensus price target of $207.07 suggests 33% upside potential, making it attractive for investors comfortable with biopharma volatility.
Banco Santander (SAN) trades at $14.86, down 0.47% on the day, with a bullish technical signal from moving averages and a moderate buy consensus from analysts (64% buy ratings). The company reported record profitability in H1 2026 with a net income margin of 26.25% and recently completed the Webster acquisition to expand its U.S. presence, though cash flow trends show recent operational outflows.
SAN's outlook is supported by strong profitability and strategic expansion, but risks include volatile cash flows, high leverage with a debt-to-asset ratio of 17.8, and integration challenges from acquisitions. The stock offers value with a P/E of 14.47, but investors should weigh execution risks against growth potential.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Neurocrine Biosciences Inc
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →About Banco Santander SA
Santander's focus is on retail and commercial banking. Latin America is geographically the largest operation, with Brazil by far the largest. Its continental European business is still mainly Iberian. Santander's U.K. presence is the result of the acquisition of building society Abbey. In the U.S., Santander operates a vehicle finance business and a regional bank focused on the Northeastern states.
Read more on SAN →
